ClinicalTrials.gg
CompletedNCT07436936OPTIPROTUpdated Feb 27, 2026

OPTIPROT, Targeted Precision Nutrition for Protein Needs in Ageing

An observational study in Healthy Aging, Nutritional Status and Dietary Protein, sponsored by Fundació Eurecat. Completed at 1 site in Spain. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Fundació Eurecat · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscle Weakness with a site in Spain — 3 open to participants now, 5 under way, none of them phase 3. Muscle Weakness · Spain.

Started
2024
with 1 other
Observational
8 of 27
none open now
Registered
25th of 27
by date
Lead sponsor
1 of 27
Fundació Eurecat

Among the 27 studies in Muscle Weakness with a site in Spain, this one is one of 2 that started in 2024, is one of 8 observational ones, and was the 25th registered.

Muscle Weakness

478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.

Browse Muscle Weakness studies →

Open to participants now

3 of the 27 studies in Muscle Weakness with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscle Weakness with a site in Spain, or all of them as a file.
02

Study summary

This multicenter, cross-sectional observational study aims to use precision nutrition tools to identify metabolic clusters in adults aged 50-75 years, enabling tailored nutritional and protein recommendations based on specific metabolic characteristics. Conducted at Eurecat-Reus (Catalonia) and AZTI (Bizkaia), the study will enroll 200 participants (75 at Eurecat, 125 at AZTI). Analyses will include metabolomics, gut microbiota profiling, epigenomics, and glycomics, with the goal of refining dietary guidelines and protein intake recommendations to address the specific needs of aging populations.

Read the detailed description

The study hypothesizes that metabolic characterization using precision nutrition tools in adults aged 50 to 75 will enable the identification of clusters with similar metabolic profiles, thereby enhancing our understanding of each group's nutritional needs and facilitating the development of tailored dietary recommendations, particularly regarding protein intake. This multicenter, cross-sectional observational study will recruit 200 participants, 75 at Eurecat-Reus (Catalonia) and 125 at AZTI (Bizkaia), and will integrate metabolic, clinical, anthropometric, lifestyle, dietary, and microbiota data to form these clusters. The primary objective is to establish metabolic profiles and clusters using precision nutrition tools, while secondary objectives include identifying biomarkers associated with health and aging, assessing the relationship between protein intake and metabolic health, and exploring the associations between gut microbiota composition, glycomic patterns, and metabolic status. Participants will attend two visits: an initial visit for eligibility confirmation and informed consent, followed by a second fasting visit for blood sampling, anthropometric measurements, collection of pre-obtained samples, and the administration of validated questionnaires on lifestyle, dietary intake, and physical activity. Ultimately, the integrated analysis of these data will refine nutritional recommendations to better address the specific metabolic needs of each cluster, thereby improving dietary guidance and overall metabolic health in the aging population.

03

Conditions studied

  • Healthy Aging
  • Nutritional Status
  • Dietary Protein
  • Muscle Weakness

Browse trials for

Keywords

  • precision nutrition
  • aging
  • dietary protein intake
  • gut microbiota
  • nutritional requirements
  • metabolomics
  • epigenomics
  • glycomics
  • anthropometry
  • healthy aging
  • muscle strength
  • omics science
  • muscle mass
  • Targeted Dietary Intervention
  • Targeted nutrition
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The cohort of the proposed study consists of 200 adults aged 50 to 75 years, who are recruited from two different research centers (Eurecat and AZTI) in Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women or men
  • Age: ≥ 50; ≤ 75 years
  • : 18.5-35 kg/m² and stable weight for at least 3 months (without weight gain or loss >3 kg).
  • Ability to read, write, and speak in Catalan or Spanish.
  • Signing of the form.

Exclusion criteria

Exclusion Criteria

  • Age ≤ 49 or ≥ 76 years
  • : ≤18.5; ≥ 35
  • Pregnant or lactating women
  • Presence of chronic or disease or metabolic condition that significantly alters nutritional requirements, such as: type I diabetes, celiac disease, inflammatory bowel disease, chronic kidney disease, severe liver disease, uncontrolled thyroid disorders, cancer, food allergies or intolerances, musculoskeletal disorders, moderate or severe cognitive impairment, or immobilization in the last 6 months.
  • Alcohol consumption:Men: Consuming 4 or more Standard Drink Units (SDUs)* per day or 28 SDUs per week. Women: Consuming 2 or more Standard Drink Units (SDUs)* per day or 17 SDUs per week.
  • Individuals currently participating or who have participated in a clinical trial involving medications or nutritional intervention within the last 30 days before study inclusion.
  • Recent use of antibiotics in the last two weeks.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • 200 adults aged 50 to 75 years

    200 adults aged 50 to 75 years, who are recruited from two different research centers (Eurecat and AZTI) in Spain.

06

What researchers measure

Primary outcomes

  1. Identification of nutritional clusters based on metabolic and biomarker profiles

    Development of group-based precision nutrition recommendations derived from metabotyping approaches, with special emphasis on protein requirements, by clustering individuals aged 50-75 according to metabolic variables, gut microbiota composition, and classical anthropometric, biochemical, and clinical biomarkers.

    Time frame: At day 1

  2. Determination of Protein Intake Requirements for Each Cluster

    stablishing specific protein intake needs for each identified cluster to optimize nutritional recommendations tailored to the metabolic and physiological characteristics of the target population.

    Time frame: At day 1

Secondary outcomes

  1. Epigenomic Profile Characterization of a Study Subcohort

    Analysis of epigenetic modifications in a subset of participants to refine the precision nutrition algorithm by incorporating epigenomic influences on metabolism and nutrient utilization.

    Time frame: At day 1

  2. Glycomic Profile Characterization of a Study Subcohort

    Examination of glycan composition and glycosylation patterns in a subset of participants to assess their role in metabolic health and further personalize the group-based nutrition strategy.

    Time frame: At day 1

  3. Validation of Group-Based Precision Nutrition Algorithm

    Integration of metabolic, microbiota, and biomarker-based clustering with epigenomic and glycomic data to improve the accuracy of the group-based precision nutrition algorithm.

    Time frame: At day 1

07

Study locations

1 site
  • Fundació Eurecat
    Reus, Tarragona 43202, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jan 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 27, 2026
StartActual
Jul 11, 2024
Primary completionActual
Jan 24, 2025
CompletionActual
Jan 24, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436936
Lead sponsor
Fundació Eurecat
Collaborators
Fundacion Azti
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Jul 11, 2024
Primary completion
Jan 24, 2025
Completion
Jan 24, 2025
Last update
Feb 27, 2026

Study contacts

Noemí Boqué, PhD
principal investigator · Fundació Eurecat

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion